Abstract
O2-6-2 - A randomized phase II trial of triplet or doublet antiemetic therapy in lung cancer patients receiving MEC (NLCTG1002)
Full Text
Sign-in/Register to access full text options
Published version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date